Tetraphase pharmaceuticals inc (TTPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-12,124

-

-

-

-19,488

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-21,481

-19,558

-9,543

-21,576

-23,476

-30,007

-31,811

-29,458

-21,110

-17,168

-16,741

-18,116

-18,043

-26,044

-20,986

-20,551

-14,205

-18,463

-13,523

-11,303

-10,116

-5,426

-2,791

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

112

113

115

204

201

219

120

121

116

116

114

111

90

72

69

67

62

65

34

32

32

39

28

25

25

32

36

36

Non-cash interest expense related to notes payable

-

0

164

234

223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing costs and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

93

41

53

62

70

78

87

93

84

Accretion of final interest payment on term loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

45

19

26

32

38

44

50

55

50

Fair value adjustment of warrants and investor right obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-263

Stock-based compensation expense

480

832

1,171

1,709

2,723

3,249

3,516

3,393

2,971

2,605

3,122

3,160

3,076

3,328

2,809

4,176

3,625

1,274

3,877

2,840

1,845

1,180

1,066

1,139

-

-

280

55

Gain from modification of operating lease

68

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on asset disposal

71

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-2

-1

0

0

-1

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

203

-207

-19

-89

-457

-323

-515

-101

-1,440

1,088

883

979

-86

-2,237

-862

-307

1,085

-357

-2,056

2,021

1,505

610

-674

311

-428

-778

1,000

-540

Inventory

-806

-839

-530

616

1,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-927

-613

-328

634

-262

-2,627

-730

-899

548

889

376

1,288

-2,753

1,437

-1,787

3,330

1,110

-361

-287

1,052

-414

829

233

551

-1,457

1,787

237

-413

Accounts payable

-452

677

-327

-613

-518

-244

1,335

-1,480

-1,707

-3,587

1,975

3,323

1,040

1,079

1,052

-1,367

1,121

-4,051

276

1,405

368

-2,987

2,799

2,044

-1,034

952

-69

461

Accrued expenses and other liabilities

-559

-2,773

-3,255

2,564

-2,387

2,488

435

2,577

-6,409

-344

749

339

4,072

-356

-777

427

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and accrued final interest payment on term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-671

446

-834

-

-435

1,876

-1,207

814

1,241

1,262

-127

Deferred revenue

-

0

0

0

-6

-3

-100

-7,370

6,819

-122

-766

697

-404

-117

-184

469

524

-139

-494

760

234

24

0

-92

-150

242

-333

-366

Operating lease right-of-use assets

360

360

353

347

342

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-363

-352

-339

-333

-328

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-18,745

-16,304

-11,550

-15,992

-16,582

-20,847

-19,562

-19,716

-15,353

-17,744

-12,159

-12,367

-9,203

-8,056

-5,339

-1,908

Net cash used in operating activities

-11,155

-10,939

-15,976

-16,636

-20,119

-16,425

-13,007

-11,302

-18,894

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Proceeds from sale of property and equipment

130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

0

2

8

98

99

17

5

83

86

9

172

504

22

103

72

136

-12

663

51

19

116

27

29

86

21

12

10

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-504

-22

-103

-72

-136

12

-663

-51

-19

-116

-27

-29

-86

-21

-12

-10

Proceeds from sale of common stock, net of underwriter discounts and issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45,599

0

5,117

68,688

Net cash provided by (used in) investing activities

130

574

10

-8

-98

-1,849

-3,017

-5

-83

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Proceeds from issuance of term loan payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,000

Repayment of debt, including final payment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,646

1,380

1,620

1,581

1,545

1,509

1,314

714

695

Proceeds from sale of common stock and prefunded warrants under a concurrent private placement and registered direct offering, net of issuance costs

15,931

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under "at-the-market" equity offering sales agreement, net of issuance costs

-

-

-

-

-

-

-

-

-

1,673

69,160

16,469

5,234

-

-

-

-

0

-294

162,445

-

-

-

-

-

-

-

-

Proceeds from issuance of stock under stock plans

1

-

-

-

-

88

9

131

231

244

72

206

88

91

101

15

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

15,932

-

-

-

-

29,091

2,281

4,844

231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

4,907

-3,269

-46,446

-16,605

-20,217

10,817

-13,743

-6,463

-18,746

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,246

-

106

127

240

-

7

1

9

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

5,322

91

101

15

171

1,215

1,984

159,045

80,417

-1,514

-1,454

-1,305

44,169

-1,307

4,404

71,002

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-9,945

-13,927

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,235

-11,552

-16,049

-16,547

-19,620

-18,241

139,278

65,045

-19,374

-13,640

-13,701

34,880

-9,384

-947

69,084

Supplemental cash flow disclosures from investing activities
Cash paid for interest

-

0

481

935

539

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

266

-266

363

344

163

201

237

273

308

328

233

Issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

236

-

-

-

-

-

-

-

-

Fair value of warrants issued in connection with issuance of term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

115

Conversion of convertible preferred stock into common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

0

0

79,832

Reclassification of warrant liability to additional paid-in-capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

462